These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials. Gul S; Ozcan O; Asar S; Okyar A; Barıs I; Kavakli IH J Biomol Struct Dyn; 2021 Oct; 39(17):6772-6791. PubMed ID: 32752938 [TBL] [Abstract][Full Text] [Related]
23. Targeting SARS-CoV-2 main protease: structure based virtual screening, in silico ADMET studies and molecular dynamics simulation for identification of potential inhibitors. Uniyal A; Mahapatra MK; Tiwari V; Sandhir R; Kumar R J Biomol Struct Dyn; 2022 May; 40(8):3609-3625. PubMed ID: 33226303 [TBL] [Abstract][Full Text] [Related]
24. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease. Mandour YM; Zlotos DP; Alaraby Salem M J Biomol Struct Dyn; 2022 Mar; 40(5):2327-2338. PubMed ID: 33094680 [TBL] [Abstract][Full Text] [Related]
25. Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment. Jung LS; Gund TM; Narayan M Protein J; 2020 Dec; 39(6):619-630. PubMed ID: 33185784 [TBL] [Abstract][Full Text] [Related]
26. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL Froggatt HM; Heaton BE; Heaton NS J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534 [TBL] [Abstract][Full Text] [Related]
27. Antiviral Drug Discovery for the Treatment of COVID-19 Infections. Ng TI; Correia I; Seagal J; DeGoey DA; Schrimpf MR; Hardee DJ; Noey EL; Kati WM Viruses; 2022 May; 14(5):. PubMed ID: 35632703 [TBL] [Abstract][Full Text] [Related]
28. An Updated Review on SARS-CoV-2 Main Proteinase (M Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134 [TBL] [Abstract][Full Text] [Related]
29. Withanone from Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of the effects of chlorhexidine and several flavonoids as antiviral purposes on SARS-CoV-2 main protease: molecular docking, molecular dynamics simulation studies. Tatar G; Salmanli M; Dogru Y; Tuzuner T J Biomol Struct Dyn; 2022 Oct; 40(17):7656-7665. PubMed ID: 33749547 [TBL] [Abstract][Full Text] [Related]
31. Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease. Tan H; Hu Y; Jadhav P; Tan B; Wang J J Med Chem; 2022 Jun; 65(11):7561-7580. PubMed ID: 35620927 [TBL] [Abstract][Full Text] [Related]
32. Precision therapeutic targets for COVID-19. Krumm ZA; Lloyd GM; Francis CP; Nasif LH; Mitchell DA; Golde TE; Giasson BI; Xia Y Virol J; 2021 Mar; 18(1):66. PubMed ID: 33781287 [TBL] [Abstract][Full Text] [Related]
33. Emetine, a potent alkaloid for the treatment of SARS-CoV-2 targeting papain-like protease and non-structural proteins: pharmacokinetics, molecular docking and dynamic studies. Snoussi M; Redissi A; Mosbah A; De Feo V; Adnan M; Aouadi K; Alreshidi M; Patel M; Kadri A; Noumi E J Biomol Struct Dyn; 2022; 40(20):10122-10135. PubMed ID: 34254564 [TBL] [Abstract][Full Text] [Related]
34. On the search for COVID-19 therapeutics: identification of potential SARS-CoV-2 main protease inhibitors by virtual screening, pharmacophore modeling and molecular dynamics. Hassan A; Arafa RK J Biomol Struct Dyn; 2022 Oct; 40(17):7815-7828. PubMed ID: 33749545 [TBL] [Abstract][Full Text] [Related]
35. Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 M Mohan A; Rendine N; Mohammed MKS; Jeeva A; Ji HF; Talluri VR Mol Divers; 2022 Jun; 26(3):1645-1661. PubMed ID: 34480682 [TBL] [Abstract][Full Text] [Related]
36. Remdesivir analogs against SARS-CoV-2 RNA-dependent RNA polymerase. Ahmed S; Mahtarin R; Islam MS; Das S; Al Mamun A; Ahmed SS; Ali MA J Biomol Struct Dyn; 2022; 40(21):11111-11124. PubMed ID: 34315339 [TBL] [Abstract][Full Text] [Related]
39. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease. Kandeel M; Abdelrahman AHM; Oh-Hashi K; Ibrahim A; Venugopala KN; Morsy MA; Ibrahim MAA J Biomol Struct Dyn; 2021 Sep; 39(14):5129-5136. PubMed ID: 32597315 [TBL] [Abstract][Full Text] [Related]
40. Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm. Verma AK; Aggarwal R Chem Biol Drug Des; 2021 Apr; 97(4):836-853. PubMed ID: 33289334 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]